ACH-HYDROXYCHLOROQUINE SULFATE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

HYDROXYCHLOROQUINE SULFATE

から入手可能:

ACCORD HEALTHCARE INC

ATCコード:

P01BA02

INN（国際名）:

HYDROXYCHLOROQUINE

投薬量:

200MG

医薬品形態:

TABLET

構図:

HYDROXYCHLOROQUINE SULFATE 200MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

ANTIMALARIALS

製品概要:

Active ingredient group (AIG) number: 0107403001; AHFS:

認証ステータス:

APPROVED

承認日:

2020-10-19

製品の特徴

_ACH-HYDROXYCHLOROQUINE SULFATE (Hydroxychloroquine sulfate tablets) _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-HYDROXYCHLOROQUINE SULFATE
Hydroxychloroquine Sulfate Tablets
Tablets, 200 mg, Oral
USP
ATC Code: P01BA02
Anti-Inflammatory – Antimalarial – Aminoquinolines
Accord Healthcare Inc.
Date of Initial Authorization:
3535 boul. St. Charles, Suite 704
October 19, 2020
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
January 6, 2023
Submission Control Number: 270069
_ACH-HYDROXYCHLOROQUINE SULFATE (Hydroxychloroquine sulfate tablets) _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
01/2022
7 WARNINGS AND PRECAUTIONS, Hematologic
01/2022
7 WARNINGS AND PRECAUTIONS, Musculoskeletal
01/2022
7 WARNINGS AND PRECAUTIONS, Psychiatric
01/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
01/2022
7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
01/2022
7 WARNINGS AND PRECAUTIONS, Skin
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
........................